2022_Sep_ConnectinPharma_Easyfairs_Geneva

About

Peter Noymer is Chief Executive Officer of Kedalion Therapeutics and has more than 20 years of experience in research, development and commercialisation of pharmaceutical products with novel delivery technologies. Before joining Kedalion, he was Chief Operating Officer at SteadyMed Therapeutics, focused on developing novel products with the PatchPump™ technology. Earlier, Peter was Vice-President of Product R&D at Alexza Pharmaceuticals, where, during his time there, the company obtained US and EU approval for Adasuve®(loxapine), the first inhalable treatment for agitation associated with schizophrenia or bipolar I disorder. Prior to Alexza, Dr Noymer held various management positions at Aradigm Corporation. He received MS and PhD degrees in engineering from MIT, and a BS degree in engineering from Princeton University.

Top